Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: kha vu who wrote (21254)	5/20/1998 9:25:00 PM
From: Hippieslayer	Read Replies (1) \| Respond to of 32384

I think the difference is in how ENMD was covered in the press or more how is was plastered all over the press after it's findings. LGND usually gets a passing mention but there needs to be a cover piece on the company to get the average joe interested. It also doesn't really help when lgnd's first NDA is going to be a drug that relatively few people have. What I think will finally get the stock into higher ground is either more recs or when it starts to show a profit. Of course, if human clinicals--not animal studies--show a hi respondence rate-say 71% of females taking targetin in phase 2 trials had complete remission of their breast cancer when other courses of therapy failed, I think you'll see LGNd rocket to 100!!!!!!! until, then we have to continue dreaming.